Treatment of schizophrenia in low-income countries

International Journal of Neuropsychopharmacology

Volumn 2, Issue 4, 1999, Pages 321-325

  Emsley, Robin A ^a   Oosthuizen, Pieter P ^b   Joubert, Andre F ^b   Hawkridge, Susan M ^b   Stein, Dan J ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b NONE

Author keywords

Low dose classical antipsychotics; Low income countries; Novel antipsychotics; Schizophrenia

Indexed keywords

EID: 0001064344     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145799001613     Document Type: Article

References (36)

1. Andreasen NC (1991). Assessment issues and the cost of schizophrenia. Schizophrenia Bulletin 17, 408-410.
2. Baldessarini RC, Cohen BM, Teicher MH (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45, 79-91.
3. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD (1999). Randomised double blind comparison of the inidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry 174, 23-30.
4. Carman J, Peuskens J, Vangeneugden A (1995). Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. International Journal of Psychopharmacology 10, 207-213.
5. Coryell W, Miller DD, Perry PJ (1998). Haloperidol plasma levels and dose optimization. American Journal of Psychiatry 155, 48-53.
6. De Hert M, Thuys E, Boydens J, Gilis P, Kesteloot K, Verhaegen L, Peuskens J (1998). Health care expenditure on schizophrenia patients in Belgium. Schizophrenia Bulletin 24, 519-527.
7. Desjarlais R, Eisenberg L, Good B, Kleinman A (Eds) (1995). World Mental Health: Problems and Priorities in Low-Income Countries. Oxford: Oxford University Press.
8. Donlon PT, Hopkin JT, Tupin JP, Wicks JJ, Wahuba M, Meadow A (1980). Haloperidol for acute schizophrenia patients: an evaluation of three oral regimens. Archives of General Psychiatry 37, 691-695.
9. Evers SM, Ament AJ (1995). Costs of schizophrenia in The Netherlands. Schizophrenia Bulletin 21, 141-153.
10. Franz M, Lis S, Pluddemann K, Gallhofer B (1997). Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. British Journal of Psychiatry 170, 422-425.
11. Glazer WM, Johnstone BM (1997). Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry 58 (Suppl. 10), 50-54.
12. Gous AGS, Holdemess MC, Mokhobo KP, Moller H, Summers RS (1996). South African Standard Treatment Guidelines and Essential Drugs List for Primary Health Care. Pretoria: Department of National Health.
13. Haro JM, Salvador Carulla L, Cabases J, Madoz V, Vasquez Barquero JL (1998). Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. British Journal of Psychiatry 173, 334-340.
14. Kapur SR, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipurski R (1996). High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry 153, 948-950.
15. Knapp M (1997). Costs of schizophrenia. British Journal of Psychiatry 171, 509-518.
16. Lieberman JA (1996). Atypical antipsychotic drugs as a first-line treatment of schizophrenia : a rationale and a hypothesis. Journal of Clinical Psychiatry 57 (Suppl. 11), 68-71.
17. Marder SM (1996). Management of treatment-resistant patients with schizophrenia. Journal of Clinical Psychiatry 57 (Suppl. 11), 26-30.
18. Maynard A, Bloor K (1998). Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals. British Journal of Psychiatry 173 (Suppl. 36), 12-18.
19. McEvoy JP, Hogarty GE, Steingard S (1991). Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 48, 739-745.
20. Meltzer HY, Okayli G (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. American Journal of Psychiatry 152, 183-190.
21. Murray CJ, Lopez AD (1997). Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349, 9063, 1436-1442.
22. National Advisory Mental Health Council (1993). Health care reform for Americans with severe mental illnesses. American Journal of Psychiatry 150, 1447-1465.
23. National Health Service Executive (1996). Burden of Disease. Leeds: NHSE.
24. Pécoul B, Chirac P, Trouiller P, Pinel J (1999). Access to essential drugs in poor countries: a lost battle? Journal of the American Medical Association 281, 361-367.
25. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M (1991). Dosage of haloperidol for schizophrenia. Archives of General Psychiatry 48, 166-170.
26. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M (1997). Risperidone, negative symptoms and cognitive deficit in schizophrenia : an open study. Acta Psychiatrica Scandinavica 95, 40-43.
27. Rouillon F, Dansette GY, Le Floch C (1994). Etude de la prise en charge thérapeutique des schizophrènes et de son coût. L'Encéphale 20, 303-309.
28. Sadik N (1992). Global Development Challenges: the Population Dimension. Change, Threat or Opportunity? Vol. 4, Social Change. Kirdar U (Ed.). New York: United Nations Development Program.
29. Sartorius N, Jablensky A, Korten A, Emberg G, Anker M, Cooper JE, Day R (1986). Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychological Medicine 16, 909-928.
30. Suleiman TG, Ohaeru JU, Lawal RA, Haruna AY, Orija OB (1997). Financial cost of treating out-patients with schizophrenia in Nigeria. British Journal of Psychiatry 171, 364-368.
31. Thomas CS, Lewis S (1998). Which atypical antipsychotic? British Journal of Psychiatry 172, 106-109.
32. Tollefson DG, Sanger TM, Lu Y, Thieme ME (1998). Depressive signs and symptoms in schizophrenia. A prospective trial of olanzapine and haloperidol. Archives of General Psychiatry 55, 250-258.
33. Van Putten T, Marder SR, Mintz J (1990). A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry 47, 754-758.
34. Weiden P, Aquila R, Standard J (1996). Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry 57 (Suppl. 11), 53-60.
35. Wyatt RJ, Henter I, Leary MC, Taylor E (1995). An economic evaluation of schizophrenia in 1991. Social Psychiatry and Psychiatric Epidemiology 30, 196-205.
36. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB, and the Sertindole Study Group (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry 154, 782-791.